Eagle Health Investments LP Acquires 111,191 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Eagle Health Investments LP increased its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 107.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,291 shares of the company’s stock after purchasing an additional 111,191 shares during the period. Centessa Pharmaceuticals accounts for 1.5% of Eagle Health Investments LP’s holdings, making the stock its 21st biggest holding. Eagle Health Investments LP owned 0.14% of Centessa Pharmaceuticals worth $8,512,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Virtus Investment Advisers LLC lifted its stake in Centessa Pharmaceuticals by 6.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after purchasing an additional 583 shares in the last quarter. Coastal Bridge Advisors LLC increased its holdings in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth about $25,000. Finally, Wells Fargo & Company MN boosted its stake in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CNTA has been the subject of a number of recent research reports. Truist Financial lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a report on Monday, April 13th. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their target price for the stock from $36.00 to $40.00 in a report on Wednesday, April 1st. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $40.50 on Tuesday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. The business has a fifty day moving average of $40.16 and a 200 day moving average of $33.89. The company has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.74 and a 52-week high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, sell-side analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.